Teva Pharma

• NCT02805842

  Collaborator, Phase 3, Status unknown, 60 people, Jun 20, 2016

• NCT02311764

  Collaborator, Phase 2, Terminated, 16 people, Dec 8, 2014

• NCT01935492

  Collaborator, Phase 3, Completed, 420 people, Sep 5, 2013

• Colorectal neoplasia-specific amino acid profiles and their diagnostic potential: a systematic review

  Consulting or advice, Mar 28, 2026

• Glucagon-like peptide 1 receptor agonists and the clinical outcomes of inflammatory bowel disease: a systematic review and meta-analysis

  Consulting or advice, Nov 8, 2025

• Unraveling Microstructural and Macrostructural Brain Age Dynamics in Multiple Sclerosis

  Employment, Consulting or advice, Fees or honoraria, Grants or research support, Aug 19, 2025

• Association of age and disease duration with comorbidities and disability: A study of the Swiss Multiple Sclerosis Registry

  Grants or research support, Jul 30, 2022

Sources: pubmed.ncbi.nlm.nih.gov